Literature DB >> 34104920

Infliximab: A treatment option for multisystem inflammatory syndrome in children with ulcerative colitis?

Gulsum Alkan1, Melike Emiroglu1, Sadiye Kubra Tuter Oz1, Anna Carina Ergani2, Halil Haldun Emiroglu2.   

Abstract

Entities:  

Year:  2021        PMID： 34104920      PMCID： PMC8152652          DOI： 10.5152/TurkArchPediatr.2021.21057

Source DB:  PubMed          Journal:  Turk Arch Pediatr        ISSN： 2757-6256


× No keyword cloud information.
  8 in total

Review 1.  A recently explored aspect of the iceberg named COVID-19: multisystem inflammatory syndrome in children (MIS-C).

Authors:  Fatih Haslak; Mehmet Yıldız; Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Turk Arch Pediatr       Date:  2021-01-01

2.  Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome.

Authors:  Katherine F Sweeny; Yanjia J Zhang; Bonnie Crume; Colin A Martz; Melissa M Blessing; Stacy A Kahn
Journal:  Pediatrics       Date:  2021-01-07       Impact factor: 7.124

3.  The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.

Authors:  Anshuman P Malaviya; Jo Ledingham; Jill Bloxham; Aisla Bosworth; Maya Buch; Ernest Choy; Andrew Cope; John Isaacs; David Marshall; Gary Wright; Andrew J K Ostör
Journal:  Rheumatology (Oxford)       Date:  2014-05-12       Impact factor: 7.580

4.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

Authors:  Erica J Brenner; Ryan C Ungaro; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Frank M Ruemmele; Flavio Steinwurz; Fox E Underwood; Xian Zhang; Jean-Frederic Colombel; Michael D Kappelman
Journal:  Gastroenterology       Date:  2020-05-18       Impact factor: 22.682

5.  Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases.

Authors:  Jonathan Miller; Amanda Cantor; Philip Zachariah; Danielle Ahn; Mercedes Martinez; Kara Gross Margolis
Journal:  Gastroenterology       Date:  2020-06-04       Impact factor: 22.682

6.  Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.

Authors:  Philip C Robinson; Duncan Richards; Helen L Tanner; Marc Feldmann
Journal:  Lancet Rheumatol       Date:  2020-09-05

7.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2020-10-03       Impact factor: 15.483

8.  Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Paediatr Drugs       Date:  2021-01-22       Impact factor: 3.022
  8 in total
  1 in total

1.  Is It Inflammatory Bowel Disease Flare or Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19?

Authors:  Paulina Krawiec; Violetta Opoka-Winiarska; Elżbieta Pac-Kożuchowska
Journal:  J Clin Med       Date:  2022-05-13       Impact factor: 4.964
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.